Multiple Myeloma Coverage from Every Angle

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

By: Vanessa A. Carter, BS
Posted: Monday, September 13, 2021

During the 2021 Society of Hematologic Oncology (SOHO) Annual Meeting, Robert Orlowski, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues presented updated long-term survival data from the phase III MAIA trial in patients with transplant-ineligible, newly diagnosed multiple myeloma (Abstract MM-155). These investigators observed improved progression-free and overall survival in patients administered the monoclonal antibody daratumumab plus lenalidomide and dexamethasone, compared with lenalidomide and dexamethasone alone, with a 47% risk reduction in disease progression and death.

“Together with the overall survival benefit observed in ALCYONE, these results support using front-line daratumumab-based regimens to maximize progression-free survival for optimal long-term outcomes,” the investigators concluded.

This study focused on patients with transplant-ineligible, newly diagnosed multiple myeloma who were randomly assigned to receive lenalidomide and dexamethasone with (n = 368) or without (n = 369) daratumumab. Treatment was continued until disease progression or unacceptable toxicity.

The median follow-up was 56.2 months. Although the median overall survival was not reached in either arm, the risk of death was significantly reduced for patients given daratumumab (P = .0013). The median progression-free survival with lenalidomide and dexamethasone alone was 34.4 months, but it was not reached for individuals given daratumumab (P < .0001). However, the estimated 5-year progression-free survival rate for participants receiving daratumumab was 52.7%, and the estimate for those not given the monoclonal antibody was 28.7%; the overall response rates were 92.9% and 81.6%, respectively.

Treatment-emergent adverse events such as neutropenia, pneumonia, anemia, and lymphopenia affected 54.1%, 19.2%, 16.8%, and 16.5% of participants given daratumumab, versus 37.0%, 10.7%, 21.6%, and 11.2% of patients given lenalidomide and dexamethasone alone, respectively. Notably, no new safety signals were identified.

Disclosure: No disclosure information was provided.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.